IARTHealthcare · Medical DevicesThe 11 Wall Street analysts covering Integra LifeSciences Holdings Corp. hold a median 12-month price target of $16 — +21.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Integra LifeSciences Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Volatility (43): The share price moves around a lot.
Size (43): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IART, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | BMO Capital | Maintains | Market Perform | $18 → $15 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $19 → $15 |
| 30 July 2026 | Wells Fargo | Maintains | Equal-Weight | $15 → $18 |
| 30 July 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 28 July 2026 | UBS | Initiates | Neutral | — |
| 28 July 2026 | UBS | Initiates | Neutral | $19 |
| 16 July 2026 | Truist Securities | Maintains | Hold | $14 → $19 |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | $19 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 8 July 2026 | Citigroup | Maintains | Neutral | $16 → $19 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 28 May 2026 | Citigroup | Upgrade | Neutral | — |
| 6 May 2026 | Citigroup | Maintains | Sell | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Apr 2026 | Argus Research | Downgrade | Hold | — |
| 15 Apr 2026 | Truist Securities | Maintains | Hold | — |
| 11 Mar 2026 | Citigroup | Maintains | Sell | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 3 Nov 2025 | Truist Securities | Reiterates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IART appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Integra LifeSciences Holdings Corp. returned −8.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 11% of US stocks
Cheaper than 77% of US stocks
Cheaper than 70% of US stocks
Cheaper than 40% of US stocks
Higher than 29% of US stocks
Higher than 37% of US stocks
Higher than 65% of US stocks
Higher than 63% of US stocks
Higher than 29% of US stocks
Higher than 43% of US stocks
Higher than 64% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Integra LifeSciences Holdings Corp. has a market value of $1.1B and an enterprise value of $2.9B.
Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 0.8% year on year.
Net income over the same four quarters: −$7.2M, a −0.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.09.
Free cash flow in the twelve months to 30 June 2026: $11.6M.
Trailing P/E: 66.5×; forward P/E: 5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Integra LifeSciences Holdings Corp. employs 4,427 people — $372K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Integra LifeSciences Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Integra LifeSciences will release its third-quarter 2026 financial results before the market opens on October 21, 2026. Management will host a conference call at 8:30 a.m. ET that day.
Why it matters — IART watchers can note the scheduled timing for the company's quarterly results and management call.
Law firm Kirby McInerney LLP announced it is investigating potential claims against Integra LifeSciences Holdings Corporation regarding whether the company and/or senior management may have violated federal securities laws or engaged in other unlawful business practices. The firm is encouraging investors who purchased or acquired Integra securities to contact them about their rights.
Why it matters — A securities-law investigation into the company and its senior management raises potential legal and reputational concerns that IART investors would want to monitor.
Johnson Fistel, a stockholder rights law firm, announced it is investigating Integra LifeSciences Holdings Corporation on behalf of investors who may have suffered losses following flooding-related outlook cuts and a 21% decline in the company's stock. The firm is inviting affected shareholders to contact it to learn more about the investigation at no cost or obligation.
Why it matters — IART watchers would want to know about a law-firm investigation stemming from flooding-related guidance cuts and a sharp stock decline, as it may signal potential legal or governance concerns.
Johnson Fistel, a stockholder rights law firm, announced it is investigating Integra LifeSciences on behalf of investors who may have suffered losses. The investigation follows flooding-related outlook cuts and a 21% decline in the company's stock.
Why it matters — An ongoing investor-rights investigation signals potential legal and financial scrutiny related to Integra's recent stock decline and outlook cuts, which could affect shareholder confidence.
Integra LifeSciences' preliminary third-quarter revenue came in $4.3 million to $6.3 million below Wall Street estimates, sending IART shares lower. SueWallSt has notified investors of a pending investigation into potential securities claims for shareholders who lost money.
Why it matters — A revenue shortfall and a pending securities investigation signal potential legal and financial headwinds that IART investors should monitor closely.
The 11 Wall Street analysts covering Integra LifeSciences Holdings Corp. have a median 12-month price target of $16, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Integra LifeSciences Holdings Corp., 3 rate it a Buy, 6 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Integra LifeSciences Holdings Corp. 82 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Integra LifeSciences Holdings Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +21.4% from the last close, and Ticker Nerd's factor model ranks Integra LifeSciences Holdings Corp. 82 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Integra LifeSciences Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IART are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.
Integra LifeSciences Holdings Corp. returned -8.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026". Integra LifeSciences will release its third-quarter 2026 financial results before the market opens on October 21, 2026. Management will host a conference call at 8:30 a.m. ET that day.
Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction. Its portfolio includes surgical instruments, dural repair products, cerebrospinal fluid management devices, cranial stabilization tools, and regenerative tissue technologies designed for complex wound and reconstructive care. Integra LifeSciences Holdings Corporation serves hospitals, surgery centers, and specialist clinicians across a range of medical disciplines, making it an important supplier in the healthcare equipment market. Headquartered in Princeton, New Jersey, the company focuses on providing clinically oriented solutions for procedures that require precision, reliability, and specialized surgical support.
CEO Dr. Stuart M. Essig Ph.D. · 4,427 employees · United States · https://www.integralife.com
